Get access

Differential efficacy of a synthetic antagonist of VLA-4 during the course of chronic relapsing experimental autoimmune encephalomyelitis

Authors

  • Barbara Cannella,

    Corresponding author
    1. Department of Pathology (Neuropathology), Albert Einstein College of Medicine, Bronx, New York
    • Department of Pathology, Albert Einstein College of Medicine, 1300 Morris Park Ave. F140, Bronx, NY 10461
    Search for more papers by this author
  • Stefanie Gaupp,

    1. Department of Pathology (Neuropathology), Albert Einstein College of Medicine, Bronx, New York
    Search for more papers by this author
  • Ronald G. Tilton,

    1. Texas Biotechnology Corp., Houston, Texas
    Search for more papers by this author
  • Cedric S. Raine

    1. Department of Pathology (Neuropathology), Albert Einstein College of Medicine, Bronx, New York
    2. Department of Neurology, Albert Einstein College of Medicine, Bronx, New York
    3. Department of Neuroscience, Albert Einstein College of Medicine, Bronx, New York
    Search for more papers by this author

Abstract

The integrin VLA-4 has been shown to play a key role in the entry of antigen-specific T cells into the CNS during autoimmune demyelination. Treatment of animals with experimental autoimmune encephalomyelitis (EAE), a model of multiple sclerosis, with antibodies to VLA-4 is known to suppress acute disease. In the present study, a synthetic antagonist of VLA-4 (TBC 3486) was injected subcutaneously into mice adoptively sensitized for chronic relapsing EAE. TBC 3486 was administered daily for 14 days at early (before acute signs) and late time points (during chronic disease). Early treatment led to marked delay in disease onset and reduction in clinical severity and demyelination. After termination of treatment, clinical severity remained lower than in controls for more than 1 week. TBC 3486-treated animals showing no clinical signs (at the height of disease in controls) displayed moderate levels of inflammation but little damage to myelin. Late administration of TBC 3486 to animals with chronic EAE had no effect clinically. Immunocytochemistry and Western blotting of CNS tissue from acutely treated animals supported a moderate shift toward a Th2-type cytokine profile after treatment. Thus, TBC 3486 effectively delayed and reduced the acute (but not chronic) phase of EAE, and this amelioration correlated with changes in the inflammatory molecule profile. © 2002 Wiley-Liss, Inc.

Ancillary